Urgent Study: Weight-Loss Jab Users May Need Lifelong Treatment

UPDATE: A groundbreaking study from Oxford University reveals that patients using weight-loss injections like Ozempic, Mounjaro, and Wegovy may need to remain on these treatments for life. The findings, based on an analysis of over 9,300 participants, show that most users regain weight rapidly after discontinuing the jabs, raising urgent concerns for health authorities and patients alike.

Experts warn that within just 17 to 20 months of stopping treatment, individuals could regain almost all the weight they lost, a phenomenon dubbed the “Ozempic rebound.” This is significantly faster than those who lose weight through conventional dieting methods. On average, former users gain approximately one pound per month after stopping, highlighting the urgent need for long-term treatment solutions.

Professor Donal O’Shea, the HSE’s lead on obesity in Ireland, emphasized, “It’s no surprise that if you stop treatment for a chronic disease, like obesity, the effect of that treatment will stop.” The implications of this study are profound, particularly for the 37% of the Irish population who are overweight and the 23% who are obese.

Cost is another pressing issue. Most patients privately pay up to €345 a month for these injections, leading to questions about the affordability of lifelong treatment. In early 2025, over 35,000 people in Ireland utilized Ozempic for diabetes, costing the state over €11 million in just one quarter. Meanwhile, the Health Products Regulatory Authority reported seizing over 11,000 unapproved doses of weight-loss jabs within eleven months, indicating a burgeoning black market.

The implications extend beyond weight regain. The study, published in the British Medical Journal, suggests that stopping these medications not only reverses weight loss but also negates crucial heart-health benefits. Cardiometabolic improvements, such as better blood sugar control and lower cholesterol, diminish in under 18 months once treatment ceases.

While those who relied solely on diet and exercise lost an average of 5 kg over a year, their weight regain was much slower, with only 0.1 kg per month, resulting in lasting health benefits. In contrast, the rapid weight gain associated with stopping injections underscores the need for a multifaceted approach to obesity management.

Professor Susan Jebb, a prominent researcher in the field, advocates for a “lifetime solution,” suggesting that continuous treatment or supportive behavioral changes are essential for long-term obesity management. “Obesity is a chronic relapsing condition, and these treatments need to be continued for life,” she stated.

As health authorities grapple with the implications of these findings, the need for effective, sustainable treatment options has never been more urgent. The study raises critical questions about how society will support those who rely on these medications to maintain their health and well-being.

In conclusion, the latest research confirms that while weight-loss jabs provide initial success, their long-term efficacy hinges on continued use. As this story develops, the focus will be on how healthcare systems adapt to these findings and support patients in managing obesity effectively.